Peptide LibraryChondromix
Also known as: Cartilage peptide complex
Chondromix (also called Cartilage peptide complex) is a bioregulator. Chondromix is a marketed blend rather than a defined single compound, sold for cartilage and joint support. It has no single molecular mechanism because its composition is a mixture, and formulations differ between suppliers.
For research use only.
Key Facts
- CAS
- 168608-25-7
- Molecular Weight (MW)
- 408.47 g/mol
- Half-life
- Not established
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Cartilage matrix (claimed)
Research summary
Marketed cartilage-support peptide blend rather than a single characterised active ingredient, with composition varying between suppliers. Because it is a mixture, no single mechanism, sequence or pharmacokinetic profile applies to it, and no pivotal trial has evaluated any branded product under this name. Not FDA-approved and not a treatment for arthritis or joint disease.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Chondromix profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Chondromix dosage: no established human dose
Chondromix has no established human dosage. It is sold as a cartilage peptide complex whose make-up differs between sellers, and no study of it is indexed in PubMed or registered on ClinicalTrials.gov. Where it is said to contain Cartalax (Ala-Glu-Asp), that peptide has only one indexed cell-culture study.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Chondromix is a marketed blend, not a defined compound, and its ingredients are not published in an indexed source. No study has tested the blend in cells, animals or people. The one indexed study of Cartalax, a peptide some descriptions list as an ingredient, is a cell-culture experiment that attributed its findings to other peptides. Nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Possible component (analog evidence) — Cartalax (AED) among four short peptides on stem-cell neuronal differentiation (2019)Preclinical · Preclinical cell-culture study of a possible component (analog evidence)Studied an analog, not Chondromix itself | Human periodontal ligament stem cells in culture | Concentration for AED alone is not reported in the abstract; AED was tested in cell culture, not administered to an organism | In vitro, added to culture medium | — | — | GAP43 and nestin expression increased with the four-peptide combination and with KED alone. An independent effect of AED on those markers was not reported. | Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019. |
Where sources disagree
- No study of the blend reports a dose, so protocols given for Chondromix have no verifiable primary source.
- Because the blend's make-up varies, evidence for any single ingredient is not evidence for a given Chondromix product. See the Cartalax profile for that peptide.
Reconstitution
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Sequence & molecular data
| Molecular formula | C15H28N4O7S |
|---|---|
| Molecular weight | 408.47 g/mol |
| CAS number | 168608-25-7 |
| Half-life | Not established |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Chondromix is a marketed blend rather than a defined single compound, sold for cartilage and joint support. It has no single molecular mechanism because its composition is a mixture, and formulations differ between suppliers. Where it contains Khavinson-series peptides such as Cartalax, the proposed mechanism is that series' hypothesis of short peptides interacting with DNA promoter regions to influence chondrocyte gene expression — a claim resting on cell-culture and cytogenetic work from one research group. No pivotal trial has evaluated any branded Chondromix product, and the pharmacokinetics of the combination are uncharacterised.
Origin
Commercial peptide mixture; not a monographed drug.
Targets
Studies
Research statistics
1 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Chondromix is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Chondromix side effects
Chondromix has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Unknown; product-dependent
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Chondromix: frequently asked questions
What is Chondromix?
Marketed cartilage-support peptide blend rather than a single characterised active ingredient, with composition varying between suppliers. Because it is a mixture, no single mechanism, sequence or pharmacokinetic profile applies to it, and no pivotal trial has evaluated any branded product under this name. Not FDA-approved and not a treatment for arthritis or joint disease.
How does Chondromix work?
Chondromix is a marketed blend rather than a defined single compound, sold for cartilage and joint support. It has no single molecular mechanism because its composition is a mixture, and formulations differ between suppliers.
Is Chondromix FDA approved?
No. Chondromix is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Chondromix?
Compounds most often compared with Chondromix include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Peptides and AgeingExternal reference
- Class-level evidence — Tissue-specific effects of peptidesExternal reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Chondromix profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Chondromix research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →